Overview

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Status:
COMPLETED
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC